Non Small Cell Lung Cancer
Conditions
Brief summary
A prospective, two-arm, non-randomized, concurrently controlled, multi-center, open-label, treat and resect study following patients to 1 year. The study is designed to evaluate the safety and feasibility of the Aliya System for the ablation of solid tumors using pulsed electric field (PEF) energy delivery. The study is intended for adult patients with suspected or confirmed NSCLC 8th ed. Stage IA2, IA3 or IB (\>1 to ≤4 cm solitary lesion) who are surgical candidates and have not received treatment for the index tumor in the last two years.
Detailed description
This study is to evaluate the safety and initial feasibility of Pulsed Electric Field (PEF) treatment of NSCLC tumors prior to surgical resection. Treatment may be delivered via either an endoluminal (bronchoscopic) or percutaneous approach at the discretion of the clinical investigator utilizing two available device configurations: * Endoluminal: Galvanize Aliya System with commercially available TBNA Needle (e.g., PeriView FLEX) and RF probe electrode * Percutaneous: Galvanize Aliya System with compatible commercially available RF needle and RF probe electrode The study will enroll and treat up to 30 adult patients with early stage NSCLC at up to 5 clinical sites. Patients meeting all eligibility criteria who elect not to undergo the PEF treatment will be offered the opportunity to participate in a concurrent control arm. Up to 10 patients will be included in the control group. A total of up to 40 patients will be included in the study.
Interventions
pulsed electric field treatment of a single NSCLC tumor
Sponsors
Galvanize Therapeutics, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Presence of solitary NSCLC nodule 8th ed. stage IA2, IA3 or IB * Nodule measuring \> 1 cm and ≤4 cm diameter by CT size estimate (e.g. T1b, T1c, T2a), with a minimum 1 cm solid component * High pre-procedure probability of malignancy as determined by the investigator * Patient has been evaluated by a thoracic surgeon and deemed a candidate for definitive lung tissue resection * Patient is, in the opinion of the principal investigator, able to adhere to and undergo bronchoscopy, surgical procedure and post-treatment care
Exclusion criteria
* Additional pulmonary nodules requiring intervention * Patient is receiving concurrent cancer treatment (e.g. external beam radiation therapy, brachytherapy, chemotherapy, targeted therapy, immunotherapy, other focal therapy) or has received treatment for the index tumor in the last two years * Patient has implanted lung devices or electronic devices * Patient has N1 disease * Patient is immune compromised or receiving immune modulating medication * Recurrent NSCLC within 2 years of initial definitive treatment * Previous checkpoint inhibitor treatment for another cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Device and Procedure related serious adverse event rate | 30 days | The rate of system-related and procedure-related serous adverse events (SAEs) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Technical Success rate | Acute procedure | The frequency with which the clinician can access the index tumor and delivery energy |
Countries
Hong Kong, Netherlands, Spain
Outcome results
None listed